Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Silexion Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
Details : Through the collaboration, Evonik’s proprietary biodegradable long-acting PLGA microparticle formulation will used for SIL-204, Silexion’s siRNA candidate for KRAS mutated Pancreatic cancer.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
December 17, 2024
Lead Product(s) : SIL-204
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Silexion Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Availom
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : Helse Stavanger
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of an Omega-3 Fatty Acid-based Supplement on Healthy Ageing
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 29, 2023
Lead Product(s) : Availom
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : Helse Stavanger
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cellulose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : JeNaCell
Deal Size : Inapplicable
Deal Type : Inapplicable
Evonik Company JenaCell Launches Wound Dressing Epicite® Balance for Chronic Wounds
Details : epicite® balance is made of biosynthetic cellulose, a hydropolymer for innovative medical device applications. The dressing enables superior wound cleansing effects and reactivates the healing of slow-healing wounds.
Product Name : Epicite® Balance
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 14, 2023
Lead Product(s) : Cellulose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : JeNaCell
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cellulose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : JeNaCell
Deal Size : Inapplicable
Deal Type : Inapplicable
Evonik Company JeNaCell Launches Wound Dressing Epicite® Balance for Chronic Wounds
Details : epicite® balance is made of biosynthetic cellulose, a hydropolymer for innovative medical device applications. The dressing enables superior wound cleansing effects and reactivates the healing of slow-healing wounds.
Product Name : Epicite® Balance
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 13, 2023
Lead Product(s) : Cellulose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : JeNaCell
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Probiotic
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Free University of Bozen-Bolzano
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of a Selected Mixture of Probiotic Strains for Degrading Gluten During Digestion
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : Probiotic
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Free University of Bozen-Bolzano
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Allay Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATX-101 is a small product placed directly into the TKA surgical site in a simple, ‘place & go’ manner designed to add minimal extra complexity and time to the procedure.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2022
Lead Product(s) : Bupivacaine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Allay Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Phathom Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Evonik and Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan
Details : Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Product Name : Voquezna Triple Pack
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 24, 2022
Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Phathom Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : BARDA
Deal Size : $220.0 million
Deal Type : Funding
Details : Lipids, molecules that make up the building blocks of living cells, are critical to producing mRNA-based drugs. The mRNA is enclosed in a lipid nanoparticle (LNP) composed of specific lipids. The LNP protects the mRNA and delivers it safely into the cell...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : BARDA
Deal Size : $220.0 million
Deal Type : Funding
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Partnership
Evonik Strengthens Strategic Partnership with Biontech on Covid-19 Vaccine
Details : Lipids are fundamental to produce highly effective mRNA-based vaccines. Only with an increase in lipid supply can the volume of vaccine be further increased. This move marks an expansion of the partnership between Evonik and the Comirnaty, vaccine manufa...
Product Name : Comirnaty
Product Type : Vaccine
Upfront Cash : Undisclosed
November 02, 2021
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Simufilam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Cassava Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Evonik and Cassava Sciences Join Forces to Fight Alzheimer’s Disease
Details : Evonik to supply commercial quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam is a novel drug, discovered at Cassava Sciences, that targets both neuroinflammation and neurodegeneration.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 03, 2021
Lead Product(s) : Simufilam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Cassava Sciences
Deal Size : Undisclosed
Deal Type : Agreement
KEY SERVICES
Reset All
Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!
